



Alabama Medicaid Agency

501 Dexter Avenue
P.O. Box 5624
Montgomery, Alabama 36103-5624
www.medicaid.alabama.gov
e-mail: almedicaid@medicaid.alabama.gov



ROBERT BENTLEY
Governor

Telecommunication for the Deaf: 1-800-253-0799
334-242-5000 1-800-362-1504

R. BOB MULLINS, JR., MD
Commissioner

June 20, 2011

Dear Pharmaceutical Manufacturer:

This correspondence is to provide you with formal written notification of an upcoming meeting of the Alabama Medicaid Pharmacy & Therapeutics (P&T) Committee, to be held on **Wednesday, August 10, 2011**. This meeting may involve review of one or more of your company's drug products. Please note: this meeting will be held in the Commissioner's Board Room at the Alabama Medicaid Building located in Montgomery, Alabama and will begin at 9:00 a.m. All meetings of this committee are open to the public.

The following is a list of drug classes for review at this meeting:

Drug Class REVIEWS	
1. Antipsychotic Agents – AHFS 281608	

While we understand there is a level of coordination between members of the manufacturing industry and a provider through the normal course of business, Alabama Medicaid asks manufacturers to respect P&T Committee members' commitment to the State of Alabama by following the procedures available through the P&T policy. Also, as outlined in the P&T Committee Statement of Integrity, Committee members agree not to have ex parte contacts or discussions with manufacturers or representatives whose drugs are presented for review. This is specifically regarding drugs to be reviewed in an upcoming Medicaid P&T meeting.

The products included in the above referenced AHFS class are being reviewed by the P&T Committee in an effort to ensure appropriate use of antipsychotics and the safety of Alabama Medicaid recipients. These products will not be included in the Agency's Preferred Drug Program but may require prior authorization to ensure clinical appropriateness. This review will not result in products being placed on the Agency's preferred drug list and therefore, it will not be necessary for manufacturers to submit written comments. Also, the Agency will not be accepting supplemental rebate offers for products included in this review. All questions from Medicaid P&T Committee members regarding specific products and/or AHFS drug classes will be addressed by the clinical contractor or Medicaid after the clinical review of the class.

If you should have additional questions regarding this notice or if you have received this letter and are no longer the appropriate contact, please notify the Medicaid Pharmacy Program at (334) 353-4582.

Sincerely,

Bakeba R. Thomas, Associate Director
Pharmacy Clinical Support Unit